Viatris Current Deferred Revenue Over Time
| VTRS Stock | USD 13.22 0.14 1.07% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Viatris Performance and Viatris Correlation. Viatris |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viatris. If investors know Viatris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viatris listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.71) | Dividend Share 0.48 | Earnings Share (0.73) | Revenue Per Share 12.593 | Quarterly Revenue Growth (0.05) |
The market value of Viatris is measured differently than its book value, which is the value of Viatris that is recorded on the company's balance sheet. Investors also form their own opinion of Viatris' value that differs from its market value or its book value, called intrinsic value, which is Viatris' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viatris' market value can be influenced by many factors that don't directly affect Viatris' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viatris' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viatris is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viatris' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Viatris and related stocks such as Emergent Biosolutions, Bausch Health Companies, and Neurocrine Biosciences Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBS | 18.3 M | 1.4 M | 1.8 M | 1.8 M | 5.3 M | 7.9 M | 7 M | 13.2 M | 10.6 M | 101.9 M | 131.5 M | 140.4 M | 26.4 M | 30.4 M | 28.1 M |
| BHC | 26.3 M | 12.8 M | 7 M | 19.5 M | 18.8 M | 16.6 M | 26 M | 2.7 B | 167 M | 2.4 B | (52 M) | (49.9 M) | 2.1 B | 2.4 B | 2.5 B |
| NBIX | 5.4 M | 37.3 M | 2.9 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | (46.2 M) | (10.3 M) | (16.5 M) | 229.3 M | 263.7 M | 276.9 M |
| TEVA | 43.7 M | 2.6 B | 1.1 B | 1.1 B | 993 M | 735 M | 725 M | 11.4 B | 9.4 B | 8.7 B | 7.3 B | 7 B | 1.5 B | 4.9 B | 3.1 B |
| HLN | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 11 M | 11 M | 23 M | 288 M | 302.4 M |
| TAK | 195.9 B | 243.9 B | 441.8 B | 177.7 B | 459.7 B | 158.5 B | 206.4 B | 200.5 B | 119.5 B | 588 B | 616.5 B | 109.9 B | 109.9 B | 126.4 B | 120.1 B |
| ITCI | 1.7 M | 1.7 M | 1.7 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 57.7 M | 60.5 M |
| AMPH | 642 K | 642 K | 642 K | 643 K | 14 M | 643 K | 97 K | (56.1 M) | (56.1 M) | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.4 M | 1.5 M |
| ALVO | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 29.7 M | 36.9 M | 59.2 M | 38.5 M |
Viatris and related stocks such as Emergent Biosolutions, Bausch Health Companies, and Neurocrine Biosciences Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Viatris | VTRS |
| Classification | Pharmaceutical Products |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
USD 13.22
Additional Tools for Viatris Stock Analysis
When running Viatris' price analysis, check to measure Viatris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viatris is operating at the current time. Most of Viatris' value examination focuses on studying past and present price action to predict the probability of Viatris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viatris' price. Additionally, you may evaluate how the addition of Viatris to your portfolios can decrease your overall portfolio volatility.